Kinfo
CG Oncology Inc. logo

CG Oncology Inc.

CGONNASDAQHealthcare·US · USD
$78.94
-5.84 (-6.89%)
Prices as of November 17, 2026 · market closed

Price

Key statistics

Valuation
Market cap7.57B USD
Enterprise value6.60B USD
Trailing P/E-37.66
Forward P/E-29.55
PEG ratio-0.56
Price / sales1,228.10
Price / book7.64
Profitability
Gross margin-239.24%
Operating margin-4293.53%
Profit margin-15.02%
Return on assets-18.63%
Return on equity-28.29%
Income (TTM)
Revenue6.17M USD
Gross profit-174.03M USD
EBITDA-261.04M USD
Net income-237.46M USD
Diluted EPS-$2.76
Rev. growth (YoY)-3.70%
Balance sheet
Total cash984.46M USD
Total debt9.24M USD
Debt / equity0.93
Current ratio21.70
Book value / share$11.10
Cash flow (TTM)
Operating cash flow-187.28M USD
Levered free cash flow-119.27M USD
Shares & price
Shares outstanding88.31M
Float68.95M
Held by institutions113.06%
Beta0.35
50-day MA$68.04
200-day MA$66.68
52-week high$93.95
52-week low$37.01
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-06-0.81-0.64+20.99%2026-08-06-0.64-0.90−40.62%2026-06-240.150.27+80.00%2026-05-08-0.54-0.71−31.48%2026-02-27-0.58-0.51+12.07%
About CG Oncology Inc.

CG Oncology Inc. is a clinical biopharmaceutical company focused on bladder cancer, with an emphasis on bladder-sparing therapies for patients with non-muscle invasive disease. The company’s lead product candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy designed to act directly within the bladder and engage the immune system against tumors. CG Oncology is developing this therapy across multiple current clinical programs for high-risk and intermediate-risk bladder cancer settings, including combination studies with other oncology treatments. The company’s work centers on addressing unmet needs in urologic oncology through localized treatment approaches that aim to preserve the bladder while targeting disease at the source.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Arthur Kuan
Employees
142
Headquarters
Dallas, TX, United States

Frequently asked questions about CG Oncology Inc.